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Variceal Bleeding Prophylaxis"
Variceal Banding or Propranolol
ABSTRACT
Sarin, S. K., Lamba, G. S., Kumar, M., Misra, A. and
Murthy, N. S.
Background and Methods: We compared propranolol
therapy and endoscopic ligation for the primary
prevention of bleeding from esophageal varices.
This prospective, controlled trial included consecu-
tive eligible patients who had large varices (> 5mm
in diameter) that were at high risk for bleeding. The
patients were assigned to either propranolol ther-
apy, at a dose sufficient to decrease the base-line
heart rate by 25 percent, or variceal ligation, to be
performed weekly until the varices were obliterated
or so reduced in size that it was not possible to
continue treatment.
Results: Of the 89 patients, 82 of whom had
cirrhosis of the liver, 44 received propranolol and
45 underwent variceal ligation. The mean (+_.SD)
duration of follow-up in each group was 14 __-9 and
13-+ 10 months, respectively. The mean time re-
quired to achieve an adequate reduction in the heart
rate was 2.5 +_. 1.7 days; the mean number of sessions
needed to complete variceal ligation was 3.2 + 1.1.
After 18 months, the actuarial probability of bleed-
ing was 43 percent in the propranolol group and
15 percent in the ligation group (P=0.04). Twelve
patients in the propranolol group and four in the
ligation group had bleeding. Three of the four in the
ligation group had bleeding before their varices had
been obliterated. Nine patients in the ligation group
had recurrent varices, a mean of 3.7 months after the
initial treatment. Five patients in each group died;
bleeding from the varices was the cause of death of
four patients in the propranolol group and of three
in the ligation group. There were no serious
complications of variceal ligation; in the propranolol
group, treatment was stopped in two patients
because of side effects.
Conclusions: In patients with high-risk esophageal
varices, endoscopic ligation of the varices is safe and
more effective than propranolol for the primary
prevention of variceal bleeding. (N. Engl. J. Med.,
1999, 340, 988 93.)
(C)1999, Massachusetts Medical Society.
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PAPER DISCUSSION
Therapy for preventing a first variceal hemor-
rhage should be undertaken in the context of
the natural history of patients with esophageal
varices. Approximately 30 percent of patients
with compensated cirrhosis (Child-Pugh class A
and early class B) have esophageal varices as
compared with approximately 60 percent of
those with decompensated disease (class C and
advanced class B) [1]. Overall, 25 to 30 percent of
patients with known esophagal varices will
bleed from them within a two year period [2].
A first variceal hemorrhage is associated with
mortality as high as 30 to 50 percent and the risk
of death is inversely related to liver function as
measured by the Child-Pugh classification [1].
Patients with large varices, particularly those
with red color signs, and decompensated cir-
rhosis have the greatest risk for a first hemor-
rhage and the greatest chance of death. Patients
at high risk for variceal hemorrhage who are
untreated may have as much as a 40 percent
chance of experiencing hemorrhage by one year
and 60 percent chance by two years [3].
There are currently two viable treatments for
prevention of a first variceal hemorrhage. Drug
therapy with propranolol and other non-specific
beta adrenergic blocking agents reduces the
hepatic venous pressure gradient (HVPG) (mea-
sured by catheterizing an hepatic vein and
determining the difference between free hepatic
vein pressure and wedged hepatic venous
pressure) and has been shown to reduce the
risk of a first variceal hemorrhage [4]. Reduction
in risk for a first hemorrhage has not, however,
been consistently associated with a reduction in426 HPB INTERNATIONAL
mortality. Other drugs such as isosorbide-
5-mononitrate may be of value alone or in
combination with beta adrenergic blocking
agents. The combination of nitrates with beta
blockers reduces portal pressure more than
either given alone; however, long-term effects
of nitrate therapy are uncertain and may result
in a higher incidence of liver failure, particularly
in older patients [5]. A major drawback to drug
therapy is the fact that patients must be
compliant with a lifelong regimen and be able
to tolerate the medication. Complications of
drug therapy are usually not life threatening
but approximately 20 percent of patients cannot
tolerate (or have a contraindication to) propra-
nolol. Moreover, of those treated, more than
half may not achieve the desired 20 percent
reduction in hepatic venous pressure gradient
[6].
Endoscopic treatment as prophylaxis against a
first variceal hemorrhage is not widely employ-
ed outside of Japan. Endoscopic sclerotherapy
has been examined in multiple western studies
which have produced heterogeneous results [7].
Most endoscopists in these countries have
abandoned the prophylactic use of sclerotherapy
because the technique has not proven consis-
tently superior to no treatment at all. One large
trial from the United States was halted early
because patients in the prophylactic sclerother-
apy arm experienced more complications and
mortality than those in the sham endoscopy
cohort [8].
Band ligation is now recognized as the treat-
ment of choice for endoscopic prevention of re-
current hemorrhage from esophageal varices in
patients who have previously bled from varices
(secondary prophylaxis) [9]. Multiple prospec-
tive and randomized comparisons of endoscopic
band ligation with sclerotherapy for secondary
prophylaxis, as well as meta-analysis, confirmed
that the newer treatment is associated with
fewer complications, a lower incidence of recur-
rent hemorrhage and more rapid eradication of
varices as well as a survival advantage [10]. The
single disadvantage associated with endoscopic
ligation therapy is a tendency for recurrence of
esophageal varices once initial eradication of
varices has been achieved.
Two large trials have compared endoscopic
ligation with no treatment for primary preven-
tion of variceal hemorrhage. Results from these
trials showed that endoscopic ligation was
superior to no treatment at preventing a first
variceal hemorrhage [3,11]. These studies were
criticized because of failure to compare the
endoscopic method with a cohort of patients
treated with beta adrenergic receptor blockade.
Sarin et al., report the first large study
comparing endoscopic band ligation with beta
adrenergic blockade for prevention of a first
variceal hemorrhage [12]. Patients who had
portal hypertension and large esophageal
varices, predominately as a result of cirrhosis,
were treated with either endoscopic ligation or
propranolol. Patients in the two treatment arms
were well matched and were followed for a mean
of 13 months. Cirrhotics treated with endoscopic
ligation experienced an actuarial probability of
hemorrhage from varices of 15 percent as com-
pared with 43 percent in the propranolol group
(p=0.04). Five patients in each cohort died. No
serious complications occurred in either group.
The Sarin trial was criticized, in an editorial
which accompanied its publication, because the
cohort treated with propranolol had an inordi-
nately high incidence of hemorrhage [13]. Bur-
roughs suggested that the dose of the medication
may have been too low (average 70 mg) as com-
pared with the average dose used in other trials
(123 mg) [14]. This is a plausible explanation for
the poor showing in the propranolol group but it
may not be the only one. We do not know, for
example, the average height or weight of the
patients in either treatment arm. This information
is irrelevant for endoscopic treatment but if
Sarin’s patients were smaller and lighter than
those in trials from other countries the 70mg dose
may have been perfectly appropriate (doses in
the other trials ranged from 40-300 mg) [4].HPB INTERNATIONALHPB INTERNATIONAL 427
Most previous trials of propranolol for preven-
tion of a first variceal hemorrhage did not focus
on high risk patients with large varices but
included a more heterogeneous population only
some of whom were at higher risk for a first
bleeding. Only four of the nine widely cited trials
specifically enrolled patients with medium or
large sized varices [14]. More relevant perhaps, is
the observation that only one of these nine beta
blockade trials had more Child class C patients
than the current study, two did not report Child
classification, and four of the remaining six either
had fewer than 10% Child classC patients or none
at all [4]. The Sarin study contained approxi-
mately 50 percent Child B and 30 percent Child C
patients in each arm. Fourteen of the 16 patients
who experienced bleeding were those with
advanced liver disease. It is widely agreed that
patients with moderate and large size varices
experience a lower incidence of first bleeding
when treated with beta adrenergic blockade. The
beneficial effect of drug therapy for those with
advanced liver disease and large varices; how-
ever, may be less profound.
Contraindications and compliance are the two
main shortcomings of pharmacological treat-
ment. Sarin et al., excluded eight otherwise
eligible patients from his study because of
contraindications to propranolol. Two addi-
tional patients were withdrawn during the study
because of complications related to the medica-
tion. The current study determined compliance
with the drug regimen by measuring heart rates
and interviewing the patients at monthly inter-
vals for three months and then at three month
intervals. This methodology is consistent with
other studies. It is reasonable to speculate, given
the interval between compliance measurements
and the fact that bleeding in the majority of
propranolol treated patients occurred after more
than four months of follow up, that some of the
patients may not have taken the medication
consistently or perhaps stopped taking it alto-
gether, an act known to be associated with an
increased risk of hemorrhage [15]. It is also
reasonable to hypothesize (although my data is
anecdotal) that ability to comply with a drug
regimen is inversely proportional to the Child
class of the patient. In contrast to the relatively
late timing of hemorrhage in the propranolol
patients, only one of the five patients in the
endoscopic treatment arm of the Sarin study
who bled, did so after the first two months of
study. This finding confirms the commonly held
view that endoscopic eradication of varices
greatly diminishes the risk of hemorrhage.
What can we conclude from this and other
trials that have examined endoscopic ligation as
primary prophylaxis? The risk of a first variceal
hemorrhage in patients treated with endoscopic
ligation in four published trials comparing
endoscopic ligation with other therapies was:
9%; 29%; 19% and 13% [3,11,16,17]. These
results combined with those of the current study
(15% incidence) are consistent with or superior
to results obtained in propranolol treated pa-
tients in other randomized trials. Such cross-trial
comparison is not rigorous enough to permit
firm conclusions; however, the trend is clear.
Endoscopic ligation has emerged as a viable
alternative to beta blockade and other pharma-
cological treatments. Several additional large
studies comparing the endoscopic method with
drug therapies are needed before a final deter-
mination of the value of endoscopic ligation for
primary prophylaxis can be made. It is also
possible that the combination of pharmacologi-
cal and endoscopic therapies may be superior to
either treatment alone and studies aimed at
answering this question should be encouraged.
Treatment of patients who are at high risk for
a first variceal hemorrhage with endoscopic
ligation now appears justified, especially when
such patients have contraindications to or can-
not tolerate or comply with a drug regimen. I
believe that further study will reconfirm the
endoscopic method is equal or superior to the
pharmacological treatments available today.
Physician or patient preference and cost will
likely determine which treatment will dominate.428 HPB INTERNATIONAL
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When are Gallbladder Polyps Malignant?
ABSTRACT
Furukawa, H., Kosuge, T., Shimada, K., Yamamoto, J.,
Kanai, Y., Mukai, K., Iwata, R. and Ushio, K., Small
Polypoid Lesions of the Gallbladder. Differential Diagnosis
and Surgical Indications by Helical Computed Tomogra-
phy. Arch Surg., 133, 735-739.
Objectives: To demonstrate the helical computed
tomographic (CT) features of small polypoid le-
sions of the gallbladder and to establish a clinical
strategy based on CT findings for the treatment
of such lesions.
Design Validation cohort study.
Setting Tertiary care public hospital.
Patients Thirty-one patients with polypoid le-
sions of the gallbladder (G3cm) underwent CT
followed by resection.
Main Outcome Measure: The detectability of the
lesions on both unenhanced and enhanced CT and
the configuration of the lesions on enhanced CT were
prospectively evaluated in comparison with the
histopathological findings.
Results: Unenhanced CT detected 14 (45%) of the
31 lesions, whereas enhanced CT detected all of
the lesions. The detection rates of the neoplastic